A Molecular Docking Investigation of SARS- CoV-2’s Main Protease against Phytocomponents of <i>Siddha</i> Formulation <i>Vishasura Kudineer</i>

Author:

Karthik Nagarajan S.,Bakkiya Devi M.,Thillaivanan S.,Maanickha Chelvi K. S.,Kanagarajan A.

Abstract

Background: Covid-19 disease is a Wuhan, China originated acute viral respiratory illness. Even though the development of numerous vaccines, the threat of the Covid-19 virus endures nearly two years after the outbreak. The new mutant strain omicron has now spread to several countries. As a result, newer antiviral therapy is required to overcome this scenario. Objective: This study is aimed at phytocomponents in the Siddha formulation, Vishasura Kudineer (VSK), it is widely used to manage fever and respiratory ailments and may be effective in combating the ongoing pandemic of novel coronavirus disease. Methodology: The principal protease 3CLpro of this new Coronavirus (SARS-CoV-2) is a possible focus for therapeutic development since it plays a major part in disease transmission. Molecular docking investigation for all active Phytocomponents found in the Siddha formulation Vishasura Kudineer with possible targets was carried in the major Protease of SARS-CoV-2 (PDB ID:6LU7). AutoDockTools was used to design and optimize the ligand structures. Results: Molecular docking of the 9 bioactive phytocomponents as Santalic acids (-6.39), Nimbolide (-6.38), Rutin, Aristolochic acid (-6.95), Glabridin (-7.53), Indirubin (-7.23), Sabinene (-5.36), β-vetivenene (-6.79), and Zingiberene (-6.47) from in the Siddha sastric formulation, Vishasura Kudineer performed on the SARS-CoV-2 Main Protease protein’s active site (PDB ID: 6LU7). These phytochemicals had significant molecular interaction with the active residues, indicating their distinct inhibitory potencies. Conclusion: Whether this Siddha formulation could be used to effectively treat and manage COVID-19 and its variants, further research and clinical studies need to be done.

Publisher

Informatics Publishing Limited

Subject

Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3